环磷酰胺联合泼尼松治疗风湿免疫系统疾病的临床疗效对照研究

Clinical study of cyclophosphamide combined with prednisone in the treatment of rheumatic diseases

目的:观察风湿免疫系统疾病采取环磷酰胺联合泼尼松治疗的临床疗效对照分析。方法:将诊断为风湿免疫系统疾病的128例患者随机数字法分成对照组(64例)与联合组(64例)。对照组仅采取泼尼松治疗,联合组在对照组基础之上联合环磷酰胺治疗。对照两组患者临床治疗效果、不良反应发生率及治疗前后类风湿因子(RF)测定结果。结果:联合组患者临床有效率为95. 31%,对照组患者临床有效率为82. 81%,差异具有统计学意义(P <0. 05)。联合组患者不良反应率为9. 38%,对照组患者不良反应率为6. 25%,差异无统计学意义(P> 0. 05)。治疗后联合组患者RF水平明显少于对照组,差异具有统计学意义(P <0. 001)。两组治疗后关节疼痛指数和关节肿胀指数与治疗前相比均降低,且观察组显著低于对照组,差异有统计学意义(P <0. 05)。结论:在风湿免疫系统疾病的治疗中,采取环磷酰胺联合泼尼松治疗,可有效发提高临床治疗效果,降低治疗的不良反应与类风湿因子水平,效果理想。

Objective To observe the clinical efficacy of cyclophosphamide combined with prednisone in the treatment of rheumatic immune system diseases.Method 128 patients with rheumatic immune system diseases were treated in our hospital.They were randomly divided into control group(64 cases)and combined group(64 cases).The control group was only treated with prednisone,while the combined group was combined with cyclophosphamide on the basis of the control group.The clinical therapeutic effect,adverse reaction rate and the determination of rheumatoid factor(RF)before and after treatment were compared between the two groups.Results The total clinical efficacy of the combined group was 95.31%,and that of the control group was 82.81%,the difference was statistically significant(P<0.05).The adverse reaction rate of the combined group was9.38%,and that of the control group was 6.25%,there was no significant difference between the two groups(P >0.05).which was comparable.After treatment,the RF level of the combined group was significantly lower than that of the control group(P<0.001).The joint pain index and joint swelling index of the two groups were lower than those before treatment,and the observation group was significantly lower than that of the control group,the difference was statistically significant(P<0.05).Conclusion Cyclophosphamide combined with prednisone in the treatment of rheumatic immune system diseases can effectively improve the clinical efficacy and reduce the level of adverse reactions and rheumatoid factors.